Form 4: Annexon Director Granted Stock Options

Bettina M. Cockroft, a Director at Annexon, Inc., was granted 65,000 stock options with an exercise price of $4.70, vesting on June 11, 2026.

Summary

• Bettina M. Cockroft, a Director of Annexon, Inc., was granted 65,000 stock options on June 11, 2026.
• The stock options have an exercise price of $4.70 per share.
• These options are for the company's Common Stock.
• The options will vest and become exercisable on the earlier of the first anniversary of June 11, 2026, or the next Annual Meeting following June 11, 2026, provided Ms. Cockroft remains in continuous service as a director.
• The total number of shares underlying the option grant is 65,000.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a standard stock option grant to a director, which is a routine event and does not inherently signal positive or negative performance.

Positives

• Grant of stock options to a director can align management's interests with shareholders, potentially incentivizing performance.
• The exercise price of $4.70 suggests the options were granted at or near the market price at the time, indicating a standard compensation practice.
• The vesting schedule, tied to continued service and a specific date, promotes long-term commitment from the director.

Negatives

• The filing does not contain any negative financial or operational information. It solely reports a stock option grant.

Risks

• The value of the stock options is directly tied to the future performance of Annexon, Inc.'s stock price. A decline in stock price would diminish the value of these options.
• The vesting is contingent on continued service, meaning the director could forfeit the options if they leave the company before the vesting date.

Future Outlook

The future outlook is not directly addressed in this filing, which is a statement of changes in beneficial ownership. The vesting schedule for the stock options implies a forward-looking expectation of continued service and potential stock appreciation.

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, where Annexon, Inc. operates. This aligns with industry standards for executive and director compensation, aiming to retain talent and incentivize long-term value creation.

Comparison to Industry Standards

• The grant of 65,000 stock options to a director at an exercise price of $4.70 is a standard compensation practice for individuals serving on the board of directors in publicly traded companies, particularly within the life sciences sector.
• Vesting schedules tied to continued service and specific future dates (e.g., first anniversary, next annual meeting) are typical and comparable to those offered by peer companies to ensure director retention and alignment with company performance.

Stakeholder Impact

• Shareholders: The grant of options aligns director incentives with shareholder interests, potentially leading to decisions that enhance stock value. However, it also represents potential future dilution if options are exercised.
• Employees: This filing does not directly impact employees, but it reflects the company's compensation strategy for its board.
• Management: The director's compensation is structured to encourage continued service and performance.

Next Steps

• Bettina M. Cockroft is expected to remain in continuous service as a director until the vesting date of the stock options.
• The stock options will become exercisable on the earlier of June 11, 2027, or the next Annual Meeting following June 11, 2026.

Key Dates

Keywords

Annexon Inc, ANNX, Form 4, Stock Options, Director Compensation, Beneficial Ownership, Securities Exchange Act, Equity Grant